Newly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure

Study Shows Direct Volume Measurement’s Accuracy Compared to Pressure Measures

Oak Ridge, TN, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary artery diastolic pressure (PADP) monitor - two key metrics of cardiovascular congestion. Pressures, as a proxy measure, are sometimes used in guiding volume management decisions by clinicians. Data from the study demonstrated a lack of correlation between pressure measures and actual blood volume, highlighting the need for direct and 98% accurate volume measurement that the BVA-100 blood test provides.

The study titled, “Pressure-Volume Profiles in Heart Failure Across Sexes and Phenotypes,” assessed the relationship between cardiac filling pressures (a commonly used surrogate to assess blood volume) and total blood volume (TBV) measurement using Daxor’s BVA-100 blood test between sexes and left ventricular ejection fraction (LVEF), key clinical determinants of response to therapy and outcomes in heart failure.

The study results showed there was no significant difference between PADP and TBV between sexes and consistent lack of correlation between PADP and TBV. Veraprapas Kittipibul, M.D., lead investigator of the study, concluded, “The two key metrics of cardiovascular congestion, namely, intracardiac pressure and intravascular volume, were disassociated across both sexes and LVEF. Knowledge of unique pressure-volume profiles perhaps demands for distinct approaches to decongestion strategies.”

“More than 135 published peer-reviewed studies, and over a dozen this past year alone, have proven that blood volume analysis informs clinicians with critical information to manage and treat volume derangements in heart failure and many other medical conditions,” said Michael Feldschuh, President, and CEO of Daxor Corporation. “This study adds further validation that surrogate markers are not accurate for volume management compared to direct and objective measurement with blood volume analysis. Mounting evidence continues to support substantial improvements in mortality reduction, hospital readmission and length of stay, and costs from the use of our highly accurate diagnostic.”

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR